A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and Stem Cell Transplantation in Patients with B-cell Non-Hodgkin's Lymphoma
[Protocol 06-150] |
Castro-Malaspina, Hugo, MD |
A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with B cell Lymphoid Malignancies
[Protocol 06-066] |
Barker, Juliet, MBBS |
A Non-Randomized Phase III Study of Response-Adapted Therapy for the Treatment of Children with Newly Diagnosed High-Risk Hodgkin Lymphoma
[Protocol 10-177] |
Trippett, Tanya, MD |
A Phase I Study of Brentuximab Plus Combination Chemotherapy as Initial Therapy for Systemic Anaplastic Large Cell Lymphoma
[Protocol 11-092] |
Horwitz, Steven, MD |
A Phase I Study of Ipilimumab in Children, Adolescents, and Young Adults with Treatment-Refractory Cancer
[Protocol 10-193] |
Wexler, Leonard, MD |
A Phase I Study of Oral LEE011 in Patients with Advanced Solid Tumors or Lymphomas
[Protocol 10-211] |
Gerecitano, John, MD, PhD |
A Phase I Study of PF-05082566 Alone in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
[Protocol 11-085] |
Segal, Neil, MD, PhD |
A Phase I Study of PU-H71 in Patients with Advanced Cancer
[Protocol 11-041] |
Gerecitano, John, MD, PhD |
A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
[Protocol 05-103] |
Gerecitano, John, MD, PhD |
A Phase I/II Study of Sequential Chemoradiation Followed by Autologous Stem Cell Transplant in Patients with Untreated Advanced Mantle Cell Lymphoma
[Protocol 11-095] |
Zelenetz, Andrew, MD, PhD |
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024] |
O'Reilly, Richard, MD |
A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
[Protocol 11-013] |
Noy, Ariela, MD |
A Phase I/II Trial of Vorinostat in Combination with Cyclophosphamide, Etoposide, Prednisone, and Rituximab for Elderly Patients with Relapsed Diffuse Large B-Cell Lymphoma
[Protocol 08-045] |
Straus, David, MD |
A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
[Protocol 10-174] |
Gerecitano, John, MD, PhD |
A Phase II Study of CAL-101 in Patients with Relapsed or Refractory Hodgkin Lymphoma
[Protocol 11-111] |
Moskowitz, Alison, MD |
A Phase II Study of CAL-101 plus Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
[Protocol 10-224] |
Lamanna, Nicole, MD |
A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma
[Protocol 11-125] |
Omuro, Antonio, MD |
A Phase II Study of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim PET Imaging
[Protocol 10-153] |
Straus, David, MD |
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
[Protocol 11-059] |
Gerecitano, John, MD, PhD |
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050] |
O'Reilly, Richard, MD |
A Phase III Study of SGN-35 versus Placebo in Patients at High Risk of Residual Hodgkin Lymphoma After Autologous Stem Cell Transplant
[Protocol 10-027] |
Moskowitz, Craig, MD |
A Study of Physician Communication Skills to Promote Patients' Transition to Survivorship
[Protocol 11-180] |
Kissane, David, MD |
A Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin's Lymphoma
[Protocol 07-147] |
Perales, Miguel-Angel, MD |
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
[Protocol 00-069] |
Offit, Kenneth, MD |
Biaxin (Clarithromycin)-Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
[Protocol 07-038] |
Portlock, Carol, MD |
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
[Protocol 06-014] |
Barker, Juliet, MBBS |
High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B-Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients
[Protocol 10-181] |
Noy, Ariela, MD |
Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
[Protocol 11-050] |
Hamlin, Paul, MD |
PDX-017: A Phase III Study of Pralatrexate Versus Observation in Patients with Peripheral T-Cell Lymphoma Following Initial Chemotherapy
[Protocol 10-212] |
Horwitz, Steven, MD |
Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
[Protocol 07-100] |
Palomba, M. Lia, MD |
Phase III Study of Ofatumumab versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
[Protocol 11-079] |
Matasar, Matthew, MD |
Risk-Adapted Therapy for Patients With Untreated Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B-Cell Lymphoma
[Protocol 08-026] |
Moskowitz, Craig, MD |
Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
[Protocol 09-063] |
Noy, Ariela, MD |
